



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/661,966
		Filing Date	September 11, 2003
		First Named Inventor	Richard B. ROTH
		Art Unit	2812
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	10	Attorney Docket Number	524592003800

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form PTO-1449, 3 pgs + duplicate 57 References Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

CUSTOMER NO. 25225**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**


Firm or Individual name	MORRISON & FOERSTER LLP Bruce D. Grant - 47,608
Signature	
Date	June 22, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 22, 2004

Signature:


(Rhea Amid)



PATENT
Docket No. 524592003800

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on June 22 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Richard B. ROTH et al.

Serial No.: 10/661,966

Filing Date: September 11, 2003

For: METHODS FOR IDENTIFYING
SUBJECTS AT RISK OF MELANOMA
AND TREATMENTS THEREOF

Examiner: Not Yet Assigned

Group Art Unit: 2812

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. §1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

Applicants respectfully request the Examiner to make note of related U.S. Patent Application Serial Nos. 10/703,817, 10/704,513 and 10/703,789, all filed on November 6, 2003.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does


not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **524592003800**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 22, 2004

Respectfully submitted,

By:


Bruce Grant
Registration No. 47,608

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7962
Facsimile: (858) 720-5125

<p>Form PTO-1449</p> <p>INFORMATION DISCLOSURE CITATION JAPAN APPLICATION</p> <p><i>U.S. P. E. JAPAN APPLICATION JUN 24 2004 PTO-1449</i></p>	Docket Number 524592003800		Application Number 10/661,966
	Applicant Richard B. ROTH et al.		
	Filing Date September 11, 2003		Group Art Unit 2812
	Mailing Date June <u>22</u> , 2004		

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	08/1996	5,547,835	Köster	435	6	
	2.	02/1997	5,605,798	Köster	435	6	
	3.	11/1997	5,691,141	Köster	435	6	
	4.	12/1998	5,849,542	Reeve et al.	435	91.1	
	5.	02/1999	5,869,242	Kamb	435	6	
	6.	07/1999	5,928,906	Köster et al.	435	91.2	
	7.	03/2000	6,043,031	Köster et al.	435	6	
	8.	02/2001	6,194,144	Köster	435	6	
	9.	07/2001	6,258,538	Köster et al.	435	6	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	10.	Barnier et al., J Biol Chem. 270(40):23381-9 (1995)
	11.	Brambilla et al., Oncogene 9:3037-3041 (1994)
	12.	Davies et al., Nature 417(6892):949-54 (2002)
	13.	Ding & Cantor, PNAS 100(6):3059-3064 (2003)
	14.	Dong et al., Cancer Res. 63:3883-3885 (2003)
	15.	East et al., Biochim. Biophys. Acta. 1572(2-3):364-386 (2002)
	16.	Elbashir et al., Methods 26:199-213 (2002)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Docket Number 524592003800	Application Number 10/661,966
		Applicant	Richard B. ROTH et al.
		Filing Date September 11, 2003	Group Art Unit 2812
		Mailing Date June <u>22</u> , 2004	

17.	Engelholm et al., J. Cell Biol. 160(7):1009-15 (2003)
18.	Eychene et al., Oncogene 10(6):1159-65 (1995)
19.	Fenster et al., Neuron 25:203-214 (2000)
20.	Fujimoto et al., J. Biol. Chem. 277:50497-50502 (2002)
21.	Fujisawa et al., Dev. Biol. 135:231-240 (1989)
22.	Hagemann and Rapp, Exp Cell Res. 253(1):34-46 (1999)
23.	Hall-Jackson et al. Chem Biol. 6(8):559-68 (1999)
24.	He & Tessier-Lavigne, Cell 90:739-751 (1997)
25.	Ikawa, Mol Cell Biol. 8(6):2651-4 (1988)
26.	Ikeda et al., J. Biol. Chem. 273:814-821 (1998)
27.	Jaiswal et al., Mol Cell Biol. 14(10):6944-53 (1994)
28.	Jelinek et al., Mol Cell Biol. 16(3):1027-34 (1996)
29.	Kohfeldt et al., J. Molec. Biol. 282:99-109 (1998)
30.	Koshiba et al., FEBS Lett. 442:138-142 (1999)
31.	Lee et al., Proc. Natl. Acad. Sci. 99:10470-10475 (2002)
32.	Marais et al., EMBO J. 14: 3136-3145 (1995)
33.	Marais et al., J. Biol. Chem. 272: 4378-4383 (1997)
34.	Mason et al., EMBO J. 18: 2137-2148 (1999)
35.	Nagase et al., DNA Res. 5:31-39 (1998)
36.	Négrier et al., Electronic Journal of Oncology 1:99-106 (2001)
37.	Oh et al., Proc. Natl. Acad. Sci. 99:383-388 (2002)
38.	Papin et al., C R Soc Biol 189(1):71-85 (1995)
39.	Papin et al., Oncogene 10(8):1647-51 (1995)
40.	Papin et al., Oncogene 12(10):2213-21 (1996)
41.	Papin et al., J Biol Chem. 273(38):24939-47 (1998)
42.	Pastuszak et al., J. Biol. Chem. 273:30165-30174 (1998)
43.	Peyssonnaux et al., Biol Cell. 93(1-2):53-62 (2001)
44.	Pollock and Meltzer, Cancer Cell. 2(1):5-7 (2002)
45.	Pollock et al., Nature Genetics 33:19-20 (2003)
46.	Pritchard and McMahon, Nat Genet. 16(3):214-5 (1997)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

<p>Form PTO-1449</p> <p style="text-align: center;">INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p>	Docket Number 524592003800		Application Number 10/661,966	
	Applicant		Richard B. ROTH et al.	
	Filing Date September 11, 2003		Group Art Unit 2812	
	Mailing Date June 22, 2004			

.	47.	Qui et al., J Biol Chem. 275(41):31921-9 (2000)
.	48.	Rajagopalan et al., Nature 418:934 (2002)
.	49.	Roth et al. Genomics 63(3):384-90 (2000)
.	50.	Schymeinsky et al., Molec. Cell. Biol. 22:6820-6830 (2002)
.	51.	Sheikh et al., J. Cell. Sci. 113(Pt 6):1021-32 (2000)
.	52.	Sithanandam et al., Oncogene 5(12):1775-80 (1990)
.	53.	Sithanandam et al., Oncogene 7(4):795-9 (1992)
.	54.	Soker et al., Cell 92:735-745 (1998)
.	55.	Stephens et al., American J. Human Genetics 68: 978-989 (2001)
.	56.	Stephens et al., Mol Cell Biol. 12(9):3733-42 (1992)
.	57.	Takashima et al., Proc. Natl. Acad. Sci. 99:3657-3662 (2002)
.	58.	Tordjman et al., Nature Immun. 3:477-482 (2002)
.	59.	Wang et al., Cell 87: 629-638 (1996)
.	60.	Weber et al., Oncogene 19: 169-176 (2000)
.	61.	Weber et al., Cancer Res. 61(9):3595-8 (2001)
.	62.	Williams & Roberts, Cancer Metastasis Rev. 13(1):105-16 (1994)
.	63.	Wojnowski et al., Nat Genet. 16(3):293-7 (1997)
.	64.	Wojnowski et al., Mamm Genome. 9(11):905-6 (1998)
.	65.	Wojnowski et al., Mech Dev. 91(1-2):97-104 (2000)
.	66.	Zhang and Guan, EMBO J. 19(20):5429-39 (2000)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	